Indication

(redirected from Indications)
Also found in: Dictionary, Thesaurus, Medical, Legal, Idioms, Encyclopedia, Wikipedia.

Indication

(1) Notice given by a dealer (through Autex) or customer of an interest in buying or selling stock, sometimes including specific volume and price; (2) approximation of where a specialist sees buy and sell interest to tighten the range to an opening price.

Indication

1. Before the start of a trading day, a rough quote given so investors and traders know the range in which a stock will begin trading. The indication may be given by officers of the stock exchange or by someone else.

2. See: Indicator.

indication

1. An estimate of the bid and ask when a security begins trading. Brokers, dealers, or investors may seek an indication before a security begins trading to help them establish a trading strategy in that security.
2. A nominal quote disseminated by a stock exchange that gives the range in which a stock will open or reopen. Also called preopening indication.
References in periodicals archive ?
Cancer Indications Apoptopic drugs in development for over 40 cancer indications, with the five most targeted indications listed below:
The top five pursued cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and prostate cancer.
Psychiatric indications covered: schizophrenia, bipolar mania, and major depression.
Early indications of activity are for central nervous system (CNS) cancer, myelodysplastic syndrome, acute leukemias and colon cancer.
Major companies are looking at different strategies in addition to new indications to protect sales of their products from generics.
New launches such as Erbitux, Avastin and Tarceva are set to continue to drive the rapid growth of the innovative market due to their utility across multiple indications, and superior efficacy profiles.
This will enable Seikagaku Corporation to develop the drug in Japan for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases, not including ophthalmic indications.
Acapodene(R) is currently being developed in separate pivotal Phase III clinical trials for two indications.
The risk factors associated with DBS have made it a last-resort therapy for most indications.
Cancer Indications Immunotherapy drugs are in development for over 40 cancer indications.
Pancreatic cancer is a second clinical indication for BrachySil(TM), currently in Phase IIb clinical trials for the treatment of inoperable primary liver cancer.
Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs.